RXRX: AI-driven platform advances rare disease and oncology programs, with major data updates ahead

Leadership transition brings renewed focus on AI-driven drug discovery, operational discipline, and talent. Proprietary data and end-to-end AI integration differentiate the platform, with strong progress in FAP and oncology programs. Key data updates and milestones are expected in the coming year.

Based on Recursion Pharmaceuticals, Inc. [RXRX] Jefferies London Healthcare Conference 2025 Audio Transcript — Nov. 18 2025